news
Lysosomes key to coronavirus shedding, finds study
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
List view / Grid view
Influenza
news
New imaging method reveals glycan vaccine targets on HIV molecules
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
news
High doses of favipiravir combat SARS-CoV-2 in hamsters
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
news
Researchers make steps towards a universal flu vaccine
A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
news
Hit-to-lead from small molecule library screens can identify new vaccine adjuvants
Researchers have screened small molecule libraries and then applied hit-to-lead approaches to discover effective vaccine adjuvants.
news
Novel targeting peptide shows promise against COVID-19 cytokine storm
Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
news
Vaccine adjuvant provides long-lasting protection against HIV in monkeys
A vaccine adjuvant named 3M-052 was able to provide rhesus monkeys with protection against HIV for over a year, a new study reports.
article
Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
article
Empty phage viruses as a method to combat influenza
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
article
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
news
Glycomimetics could prevent COVID-19 from infecting human cells
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
news
Severe COVID-19 symptoms may be caused by overactive neutrophils
An international consortium suggest that the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS), could be caused by Neutrophil Extracellular Traps (NETs).
article
How are seasonal influenza vaccines developing?
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
news
Remdesivir most promising COVID-19 drug, say researchers
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
news
Virtual reality could be used to design new drugs, say researchers
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.